data-id="" >PubMedhttps://pubmed.ncbi.nlm.nih.gov/23024237Long-term follow-up of hematologic relapse-free survival in a phase 2 ...网页2012年12月20日 · In a phase 2 trial of B-lineage ALL patients with persistent or relapsed MRD, a T cell-engaging bispecific Ab construct induced an 80% MRD response rate. In the present study, we show that after a median follow-up of 33 months, the hematologic relapse-free survival of the entire evaluable study cohort of 20 patients was 61% (Kaplan-Meier …
发布时间:2024-06-03data-id="" >PubMedhttps://pubmed.ncbi.nlm.nih.gov/22160483Dasatinib or imatinib in newly diagnosed chronic-phase chronic ... - PubMed网页2012年2月2日 · Here, 24-month data are presented. Cumulative response rates by 24 months in dasatinib and imatinib arms were: CCyR in 86% versus 82%, MMR in 64% versus 46%, and BCR-ABL reduction to ≤ 0.0032% (4.5-log reduction) in 17% versus 8%. Transformation to accelerated-/ blast-phase CML on study occurred in 2.3% with …
发布时间:2024-06-03CopyRight 2018-2019 实验室设备网 版权所有 |